CGRP monoclonal antibodies represent an important advancement in migraine treatment, helping many patients reduce migraine frequency. However, real-world evidence shows that these therapies do not work for everyone, particularly those with long-standing chronic migraines.
Clinical studies and observational data indicate that 30–50% of chronic migraine patients either fail to respond adequately to CGRP therapies or discontinue treatment due to side effects or lack of sustained benefit. This highlights an important reality: migraine pathophysiology is complex and involves more than a single biochemical pathway.
While CGRP therapies target neurogenic inflammation and vascular mechanisms, migraines also involve peripheral nerve sensitization, muscle tension, and central pain amplification. These contributing factors are not fully addressed by CGRP inhibition alone.
Botox remains a guideline-supported preventive option for chronic migraine, including in patients who do not respond to CGRP therapies. Unlike CGRP medications, Botox acts locally at nerve endings and muscles, inhibiting multiple pain-signaling neurotransmitters and reducing sustained muscle contraction
in the head and neck.
Importantly, failure of a CGRP therapy does not predict failure of Botox. Many patients who discontinue CGRP treatment experience meaningful improvement when switched to Botox due to its different mechanism of action.
Understanding the strengths and limitations of CGRP therapies allows patients and providers to make more informed treatment decisions. Migraine management is not one-size-fits-all, and sequential or complementary approaches are often necessary for optimal outcomes.
END THE MIGRAINE CYCLE, GET YOUR FREE COPY OF
The Amazing Truth About Migraine Headaches
and What Your Doctor Hasn’t Told You
Send Me The Guide Now
To schedule an appointment, Call Us 905-639-6701 or online at https://www.NabetaDentistry.com/appointment-request